CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02628535
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:19.087891+00:00
Published At: 2022-02-08T00:00:00+00:00
Record Updated At: 2022-02-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Mesothelioma", "Bladder Cancer", "Melanoma", "Squamous Cell Carcinoma of the Head and Neck", "Non Small Cell Lung Cancer", "Clear Cell Renal Cell Carcinoma", "Ovarian Cancer", "Thyroid Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer", "Colon Cancer", "Soft Tissue Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-02-08"
protocolSection.identificationModule.nctId: "NCT02628535"
protocolSection.identificationModule.officialTitle: "Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.